Monitoring for warning signs If you are currently using a GLP-1 medication, awareness of serious side effects is your first line of defense
Statinfibrate combination therapy is associated with an increased risk for abnormal transaminase levels, myositis, or rhabdomyolysis (26) and does not lower the risk of cardiovascular events more than simvastatin alone (27)
In RCTs, there are tightly regulated cohorts based on stringent in- and exclusion criteria, thereby reducing generalizability
8 It is also responsible for determining how fat is metabolized in the liver and how it is stored in the body
Developing an oral GLP-1 pill has been challenging because these peptide-based drugs are easily broken down in the stomach
Simultaneously, GLP-1 suppresses glucagon secretion from pancreatic alpha cells, reducing hepatic glucose production